EUVIMEDEUVIMED entdecken
Crossref

Engineering Liver-Targeted Carbon Dots for Hepatic Injury Therapy

Jing Zhou, Shanshan Pang, Li Qin, Rong Xu, Hongtai Shi iD, Jianhe Gan

ACS Applied Bio Materials · 09.11.2026

DOI: 10.1021/acsabm.6c01232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, online erschienen am 09.11.2026. Verfasst von Jing Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou215000, China. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Yancheng Science and Technology Bureau, State Key Laboratory of Radiation Medicine and Protection, Medical Research Project of the Health Commission of Yancheng City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With growing incidence and limited treatment modalities, drug-induced liver injury (DILI) has become a prominent unmet clinical challenge. Despite being the primary clinical hepatoprotective agent, N-acetylcysteine (NAC) is severely constrained by its insufficient therapeutic efficacy and lack of liver-targeting specificity. Herein, we present the development of liver-targeted carbon dots (HTGN-CDs) as a precision nanotherapeutic against DILI. On the one hand, GN-CDs were synthesized using NAC and glucose as precursors, with NAC incorporation significantly strengthening the antioxidative capacity of CDs. On the other hand, surface functionalization with glycyrrhetinic acid-polyethylene glycol (GA-PEG) endowed the GN-CDs with enhanced hepatocyte-targeting capability, thereby promoting their accumulation in the liver. In vitro assays confirmed the potent antioxidant and anti-inflammatory activity of GN-CDs, while in vivo studies in acetaminophen (APAP)-overdose mice demonstrated that HTGN-CDs significantly reduced hepatocyte necrosis and lowered key biochemical indicator levels, with efficacy superior to the clinical standard NAC. Mechanistically, HTGN-CDs mitigated oxidative stress via the restoration of antioxidant enzyme activity and suppressed inflammation by blocking pro-inflammatory cytokine release and macrophage infiltration. Safety assessments verified excellent biocompatibility of HTGN-CDs, with no detectable hemolytic activity, hematological abnormalities, or organ toxicity observed. Collectively, our findings highlight HTGN-CDs as a promising multifunctional nanotherapeutic for DILI, with substantial potential for clinical translation.

Schlagwörter

Stichwörter der Autor:innen

N-acetylcysteineantioxidantcarbon dotshepatic injury protectionliver-targeting

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou215000, China.
  • Department of Infectious Diseases, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng224001, China.
  • Department of Radiation Oncology, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng224001, China.

ORCID-Profile: Hongtai Shi

Förderung

  • Yancheng Science and Technology Bureau
  • State Key Laboratory of Radiation Medicine and Protection
  • Medical Research Project of the Health Commission of Yancheng City

Zitieren

APA

Zhou, J., Pang, S., Qin, L., Xu, R., Shi, H., & Gan, J. (2026). Engineering Liver-Targeted Carbon Dots for Hepatic Injury Therapy. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.6c01232

Vancouver

Zhou J, Pang S, Qin L, Xu R, Shi H, Gan J. Engineering Liver-Targeted Carbon Dots for Hepatic Injury Therapy. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.6c01232

BibTeX
@article{Zhou2026,
  author = {Zhou, Jing and Pang, Shanshan and Qin, Li and Xu, Rong and Shi, Hongtai and Gan, Jianhe},
  title = {Engineering Liver-Targeted Carbon Dots for Hepatic Injury Therapy},
  journal = {ACS Applied Bio Materials},
  year = {2026},
  doi = {10.1021/acsabm.6c01232}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche